Business
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting
IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"IRVING, Texas, March 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in San Antonio, Texas to be held March 21-26, 2026.\n \n \n \n \n \n \n \nCaris' robust multimodal database, comprised of Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), IHC and real-world clinical data, was used to generate the results being presented. The studies, including one oral presentation and four posters, will cover soft tissue and bone sarcomas, melanoma and gastrointestinal stromal tumors. These posters and presentation represent a collaborative effort between Caris and over 20 cancer centers and institutions across the United States and Europe.\"USCAP offers a great opportunity for pathologists to showcase the latest advances and publications in our industry. We're presenting across multiple topics, incorporating real‑world outcomes and uncovering insights that bring us closer to truly personalized treatment pathways,\" said Matthew Oberley, MD, PhD, SVP, Chief Clinical Officer and Pathologist-in-Chief at Caris. Oral Presentation:BCORL1::CREBBP Fusions Characterize an Aggressive Frequently Ossifying Bone and Soft Tissue Sarcoma with Predilection for the Clavicular Bone. Oral #808Platform - Tuesday PM - Bone and Soft Tissue Pathology. March 24, 2026. Presentation Time: 2:00 PM – 2:15 PM CDTPosters Include:Landscape and Molecular/Clinical Correlates of Pathogenic Gene Fusions in Melanoma: A Comprehensive Molecular Profiling Study. Poster #48Poster II - Monday PM - Dermatopathology. March 23, 2026. Time: 1:00 PM – 4:30 PM CDTComprehensive Analysis of Adult NTRK-Rearranged Sarcomas: Clinical, Pathologic, and Genomic Correlates. Poster #69Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time: 1:00 PM – 4:30 PM CDTSecondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma: Beyond NR4A3. Poster #70Poster II - Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time: 1:00 PM – 4:30 PM CDTInterplay of Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal Stromal Tumor (GIST): Correl...